introduction Heart failure (HF) is a major health problem as it poses a considerable burden on health-care services in North America and Europe, mostly because of the necessity for hospitalization to stabilize the clinical condition. Hospitalizations for HF increased in the United States by 174% from 399,000 in 1979 to 1,093,000 in 2003 [1]. In Europe, epidemiological data are similar and it is estimated that hospitalizations for acute HF (AHF) contribute to ≥60% of the total heart failure cost [2,3].
C Franssen, WJ Paulus Collagen metabolism plays a major role in determining the properties of the extracellular matrix and myocardial stiffness [18] . Indeed, in HFPEF patients with increased LV filling pressures, collagen synthesis predominates over degradation [19] . Markers of collagen metabolism [aminoterminal propeptide of collagen 3 (PIIINP), carboxy-terminal telopeptide of collagen 1 [CITP]) are elevated in HFPEF patients and markers of matrix degradation and extracellular matrix turnover [matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9)] are low [19] . Moreover, the ratio of MMP9/TIMP1 (tissue inhibitor of matrix metalloproteinase 1) was predictive for a higher left atrial volume index (LAVI) [20] .
LAVI proved to be a marker of chronically elevated LV-filling pressures [21] .
Cardiomyocytes are the second determinant of myocardial stiffness. Cardiomyocytes isolated from endomyocardial biopsies in HFPEF patients appeared to have an elevated myocardial stiffness [22] . These findings suggest that cardiomyocytes cause an exaggerated myocardial stiffness in HFPEF. The giant cytoskeletal protein titin has elastic properties that have been related to cellular stiffness and two isoforms exist: a stiffer N2B and a more compliant N2BA [23] . Titin can switch between both isoforms, which is a known mechanism to adjust myocardial stiffness. Recent studies have demonstrated the phosphorylation state of titin and the formation of disulfide bridges within the molecule to be also responsible for the increased passive stiffness in the failing heart [24] [25] [26] .
Moreover, it has been demonstrated that the frequencydependent upregulation of cardiac output is blunted as a result from progressive volume unloading of the LV due to limited relaxation reserve in combination with increased passive stiffness, despite preserved force-frequency relation [27] . LV relaxation is determined by cellular calcium-handling and cross-bridge detachment [28] , which in turn is influenced by Nitric Oxide (NO)signalling [29] as evident from a hypertensive mouse model, in which uncoupling of NO-synthase induced HFPEF [30] . Finally, knowing that cross-bridge detachment and calcium-homeostasis are energy-consuming processes, a deficit in ATP kinetics also contributes to diastolic dysfunction.
Systolic left ventricular function
As its name implies, LVEF is preserved in HFPEF. However, echocardiography studies have demonstrated a reduced longitudinal and radial shortening in HFPEF, indicative of systolic abnormalities despite preserved LVEF [31] . The abnormalities of systolic function become more apparent on exercise, indicating that HFPEF is not an isolated disorder of diastole [32] .
Exercise disturbances in HFPEF
The exercise capacity of HFPEF patients is reduced as a consequence of exaggerated stiffness of the cardiovascular system when compared with elderly persons or hypertensive patients [6, 33] . These abnormalities correlate with and may contribute to severe exercise intolerance [34] .
Secondly, exercise capacity in HFPEF is hampered by chronotropic incompetence during maximal exercise and impaired heart rate recovery after exercise [35] . Although the precise mechanism for these heart rate abnormalities is unclear, it certainly plays a role in their exertional complaints [36] .
Finally, diastolic and systolic reserve function are disturbed during exercise. Invasive measurements have demonstrated that during supine cycle ergometry or outstretched arm adduction lifting, HFPEF patients had greater increases in LV end-diastolic pressure, pulmonary capillary wedge pressure (PCWP) and right heart pressures and that they had blunted increases in heart rate, systemic vasodilation, and cardiac output compared to controls [37] .
HFPEF and HFREF: different entities?
As already mentioned, HFPEF originated from large clinical trials in heart failure [8], suggesting the difference with HFREF is merely based on LVEF. However, the evidence to consider both forms of HF as two different entities is increasing, based on clinical and preclinical data. A bimodal distribution of LVEF in chronic HF has been demonstrated, suggesting 2 different HF phenotypes [38] .
Moreover, clinical predictors for HFPEF differ from HFREF with a more prominent role for elevated systolic blood pressure, atrial fibrillation and female sex [39] . Both forms of HF are characterized by LV remodelling, which is concentric with increased wall thickness in HFPEF and eccentric with LV dilation in HFREF, suggesting different pathophysiological processes [40, 41] . These structural differences were confirmed in studies comparing myocardial histology, demonstrating a higher collagen volume fraction and a larger myocyte diameter in HFREF compared to HFPEF [42] .
Moreover, the expression of the compliant titin-N2BA isoform is higher in HFREF whereas the stiffer isoform N2B predominates in HFPEF [42, 43] . Finally, the expression of beta-adrenergic signalling molecules and markers of collagen metabolism differ between both types of HF [44, 45] . markedly abnormal haemodynamic responses during exercise [18] .
Finally, as noticed earlier, there is increasing evidence to use other biomarkers in the diagnosis of HFPEF [19, 20] . It is probable that the future diagnosis of HFPEF will include fibro-inflammatory biomarkers reflecting chronic myocardial remodelling, unaffected by instantaneous changes in volume status [47] . This may improve diagnosis in early-stage disease.
Diagnosis of acute HFPEF
There are no distinct guidelines available to diagnose acute HFPEF. Diagnosis is based on signs and symptoms of AHF. The clinical presentation is frequently a patient with pulmonary and/or peripheral oedema. According to the HFPEF-criteria [16] diastolic ACE-inhibitors were tested in PEP-CHF: The perindopril in elderly people with chronic heart failure (PEP-CHF) study [51] . This was a randomized double-blind trial in 850 elderly heart failure patients with LVEF >45%, comparing placebo with perindopril.
The only group of patients that appeared to benefit from treatment, were those with elevated systolic blood pressure and a history of myocardial infarction. Unfortunately this study was underpowered to determine the effect of perindopril on long-term morbidity and mortality. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) randomized 42,418 high-risk hypertensive patients to chlorthalidone, amlodipine, lisinopril, or doxazosin, providing an opportunity to compare these treatments with regard to occurrence of hospitalization for HFPEF or HFREF [52] . The investigators concluded that the ACE-inhibitor lisinopril was inferior to chlorthalidone in preventing new-onset HFPEF, in contrast to the prevention of new-onset HFREF.
An angiotensin receptor blocker (ARB) was studied in the Irbesartan in patients with heart failure and preserved ejection fraction trial (I-PRESERVE) [53] . 4,128 patients of >60 years and LVEF >45% in NYHA class II, III of IV heart failure received a daily dose of 300 mg of irbesartan or placebo. During a mean followup of 49.5 months, irbesartan did not improve rates of death or rates of hospitalization for cardiovascular causes compared to placebo. Candesartan was studied in the CHARM-Preserved trial [54] . 3,023 patients with NYHA class II-IV heart failure, LVEF >40% were included and assigned to candesartan or placebo without a difference in cardiovascular death during the median follow-up of 36.6 months. However, fewer patients in the candesartan group compared to placebo were admitted to hospital for an episode of AHF (230 vs. 279, p=0.017).
The results of the above mentioned trials with ACE-inhibitors and ARBs seem counterintuitive. In HFREF patients, ACE-inhibitors and ARBs have been shown to promote reverse remodelling and reduce myocardial fibrosis. The extent of myocardial fibrosis in HFPEF is less than in HFREF [42] , a finding that may explain these results. The VALIDD trial demonstrated that the ARB valsartan did improve diastolic function in hypertensive patients with a normal LVEF [55] . However, this improvement was similar in patients treated with other antihypertensive treatment, suggesting myocardial fibrosis is not to be the key pathophysiological mechanism in HFPEF.
Being a cornerstone of HFREF treatment, beta blockers were also studied in HFPEF. OPTIMIZE-HF is a registry with 7,154 HF patients in whom beta blocker therapy was initiated and patients were followed to determine the relationships between treatment and mortality, rehospitalization, and a combined mortalityrehospitalization endpoint [56] . In contrast to HFREF patients, beta blockers did not significantly influence the risk of mortality and rehospitalization. The SENIORS-trial investigated the effects of the newer beta blocker nebivolol in a placebo controlled trial in elderly patients (>70 years) with HF [57] . All-cause mortality and cardiovascular hospital admission were reduced by 14% and this effect did not differ between patients with LVEF <35% and patients with LVEF >35%. However, beneficial effects of nebivolol on LV end-systolic volume and LVEF were only recorded in patients with LVEF <35% in the primary trial. A more recent sub analysis of the SENIORS-trial demonstrated similar beneficial and promising effects of nebivolol in HFREF and HFNEF patients on the primary end point of all-cause mortality or cardiovascular hospitalizations [58] . Carvedilol was studied in the COHERE-trial [59] . Patients with HF (n=4280) were started on carvedilol and outcomes were registered according to LVEF >40% or LVEF <40%. One-year mortality rate decreased by 6% in patients with LVEF >40%, and this benefit was identical to patients with lower LVEF. However, functional status and need for hospitalizations improved more in patients with lower LVEF compared to LVEF >40%.
Finally, the effects of digoxin on morbidity and mortality in DHF
were studied in the ancillary digitalis investigation group trial [60] . 988 ambulatory chronic HF patients with normal sinus rhythm and LVEF >45% were assigned to treatment with digoxin or placebo.
During a mean follow-up of 37 months, digoxin had no effect on mortality and all-cause or cardiovascular hospitalizations.
There seem to be two main reasons for these contrasting results between HFREF and HFPEF trials [61] . First, both types of heart failure are probably different entities and characterized by different pathophysiological mechanisms as discussed earlier, resulting in the need for different treatment strategies.
The second explanation for the disappointing results of HFPEF trials is found in their methodologies. A recent review of 21 HFPEF 
Advised treatment strategies in chronic HFPEF
As mentioned above, there are no positive outcomes of large trials in HFPEF that have led to treatment guidelines being made.
Nevertheless, the ESC has provided some advice [62] .
Non-pharmacologic strategies applicable to all forms of heart failure concerning a healthy way of living should be followed. -Diuretics can be used to control sodium and water retention and relieve breathlessness. However, in many cases of isolated diastolic heart failure, pressure overload is more pronounced than volume overload.
-In cases of atrial fibrillation, effective control of the ventricular rate is mandatory.
-A heart rate limiting calcium-blocker like verapamil can be used to improve exercise tolerance and LV diastolic function assessed by echocardiography. However, this is based on a very small study in 15 elderly patients [63] .
-ACE-inhibitors and ARBs can be used to treat arterial hypertension, however, without beneficial effects in large, randomized trials as mentioned above. Treatment with perindopril leads to a reduction in mortality and HF hospitalizations after 1 year, but failed to show any difference after 3 years of treatment [51] . A modest reduction in hospitalizations for HF was achieved in patients treated with candesartan in the CHARM-Preserverd trial, without an effect on mortality [54] .
Treatment of acute HFPEF
In acutely decompensated HFPEF patients, diuretics are the mainstay of treatment, combined with the correction of arterial hypertension. As in HFREF, intravenous nitroprusside can be used to reduce blood pressure and afterload. Vasodilator therapy in HFPEF should be used with great caution, since a recent trial demonstrated that patients with HFPEF experience greater blood pressure reduction, less enhancement in cardiac output, and greater likelihood of stroke volume drop with vasodilators, as compared to HFREF [64] . In cases of haemodynamic instability, inotropic therapy can be useful. However, there are no randomized trials with dobutamine in HFPEF and this drug should be used with prudence. Moreover, a study using dobutamine stress echocardiography in HFPEF demonstrated a stress-induced increase in LV end-diastolic pressure, indicating a lack of lusitropy [65] .
Novel therapeutic strategies in HFPEF
Based on the proposed pathophysiological mechanisms of HFPEF, new therapeutic strategies are being developed. A couple of them will be discussed here. Cyclic guanosine monophosphate (cGMP) signalling plays a key role in cardiovascular disease, such as hypertension, atherosclerosis, pulmonary hypertension, cardiac hypertrophy , ventricular remodelling and diastolic dysfunction [66] . A therapy aimed at increasing levels of cGMP could thus be beneficial in stimulating cGMP-dependent protein kinases (PKG). cGMP is produced by guanylyl cyclase upon stimulation by natriuretic peptides or nitric oxide (NO) and its breakdown is controlled by Phosphodiesterases (PDE).
A first mechanism to improve cGMP-production is to enhance NO-synthase (NOS) coupling and NO-production.
Tetrahydrobiopterin (BH4) is derived from folic acid and is an essential cofactor for endothelial NOS. Diminished bioavailability of BH4 can lead to NOS-uncoupling and increased production of reactive oxygen species, associated with cardiovascular disease.
Indeed, treatment with exogenous BH4 ameliorates pre-existing advanced cardiac hypertrophy/fibrosis in mice [67] . Phase II-trials with BH4 in different cardiovascular diseases are underway. Other novel therapeutic strategies concern heart rhythm. The rationale for beta blockers was to prolong diastole. The SENIORStrial and its sub-study showed a reduction in all-cause mortality and cardiovascular hospitalizations with nebivolol [58] , but the recent ELANDD-study failed to show an improvement of longterm nebivolol on exercise capacity in HFPEF, probably because of its negative chronotropic effect [75] . Indeed, chronotropic incompetence is an important contributor to exercise intolerance [35, 36] . A newer drug, the If channel blocker ivabradine, is currently also under investigation in a HFPEF population (NCT00757055).
Device-therapy in HFPEF
Although device-therapy is an important part of the management of patients with HFREF [62, 76] , little is known about potential effects in HFPEF. However, sudden cardiac death (SCD) seems to be an important cause of death in HFPEF. An analysis of the Duke database showed 40 SCD out of 548 deaths out observed in 1,941 HFPEF patients [77] . Even more impressive, in a sub study of I-PRESERVE, SCD accounted for 25% of deaths in HFPEF [78] . The potential role of implantable cardioverter-defibrillators (ICD) needs further investigation in prospective, randomized trials.
Invasive and echocardiography measurements in 60 HFPEF patients have demonstrated that systolic dyssynchrony occurs in 33% and diastolic dyssynchrony in 58% of cases [79] . Apart from this mechanical dyssynchrony, the patients in I-PRESERVE and CHARM-Preserved had electrical dyssynchrony (left bundle branch block) in 8.1 and 14% respectively [53, 54] . Whether electrical and mechanical dyssynchrony in HFPEF patients are determinants of prognosis is currently under investigation in the KaRen project [80] . Data on the use of cardiac resynchronization therapy (CRT) in HFPEF is limited to a case report and a retrospective sub study of the PROSPECT trial in patients with LVEF >35% [81, 82] . These patients derived clinical and structural benefit from CRT and support initiation of large trials looking at CRT in HFPEF.
Conclusion
Heart failure with preserved ejection fraction is a major health care problem with a high rate of morbidity and mortality and accounts for half of all heart failure patients. Unfortunately their prognosis has remained unchanged during recent decades due to a lack of therapeutic interventions with positive outcome. However, there is hope for a better future. The diagnostic criteria have already become clearer and they will evolve further as the pathophysiology of HFPEF is being unravelled. In future diagnostic strategies, biomarkers will probably play a more important role, compared with imaging. With improved diagnostic criteria, the road for new trials with rigid inclusion criteria in HFPEF will be paved.
Promising therapeutic strategies will be investigated, based on pathophysiological mechanisms such as inflammation, fibrosis, cGMP deficit and energy shortage.
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